Stock listing
NASDAQ:NDRA ENDRA Life Sciences Inc. Stock
Home listing (NASDAQ) of ENDRA Life Sciences Inc.
Follow ENDRA Life Sciences Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:NDRA
$3.58 USD -0.46 (-11.4%)
Close on Nov 20, 2026
- Day range
- $3.42 – $3.73 USDNov 20, 2026
- Volume
- 15,674 sharesNov 20, 2026
- Market cap
- $5.36M USDAt the close on Nov 20, 2026 · price × 1.50M shares outstanding
- 52-week range
- $2.96 – $6.75 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $159,719 USDMedian day 14,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:NDRA · Home | $3.575 USD | -0.46 (-11.4%) | 15,674 | $3.70 | $3.725 | $3.42 | $4.035 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NDRA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.575 | -0.46 | -11.4% | $3.70 | $3.725 | $3.42 | 15,674 | |
| $4.035 | +0.115 | +2.9% | $3.86 | $4.055 | $3.525 | 13,925 | |
| $3.92 | -0.50 | -11.3% | $4.405 | $4.41 | $3.44 | 16,967 | |
| $4.42 | +0.01 | +0.2% | $4.46 | $4.46 | $4.32 | 4,471 | |
| $4.41 | -0.23 | -5.0% | $4.51 | $4.52 | $4.41 | 4,552 | |
| $4.64 | -0.129 | -2.7% | $4.59 | $4.96 | $4.59 | 7,418 | |
| $4.769 | -0.001 | 0.0% | $4.77 | $4.80 | $4.637 | 5,435 | |
| $4.77 | -0.07 | -1.4% | $4.78 | $5.14 | $4.77 | 10,135 | |
| $4.84 | +0.11 | +2.3% | $4.75 | $4.892 | $4.71 | 4,125 | |
| $4.73 | -0.275 | -5.5% | $4.98 | $4.98 | $4.70 | 1,161 | |
| $5.005 | +0.065 | +1.3% | $4.98 | $5.005 | $4.00 | 17,138 | |
| $4.94 | +0.08 | +1.6% | $4.75 | $4.96 | $4.75 | 7,370 | |
| $4.86 | +0.06 | +1.3% | $4.83 | $4.945 | $4.745 | 3,740 | |
| $4.80 | +0.05 | +1.1% | $4.64 | $4.885 | $4.64 | 5,777 | |
| $4.75 | -0.13 | -2.7% | $4.85 | $4.86 | $4.723 | 10,517 | |
| $4.88 | +0.14 | +3.0% | $4.91 | $5.185 | $4.69 | 14,490 | |
| $4.74 | -0.221 | -4.5% | $5.01 | $5.01 | $4.58 | 10,269 | |
| $4.961 | +0.141 | +2.9% | $4.80 | $5.00 | $4.762 | 4,279 | |
| $4.82 | +0.02 | +0.4% | $4.83 | $4.98 | $4.735 | 12,860 | |
| $4.80 | +0.02 | +0.4% | $4.68 | $4.80 | $4.655 | 4,500 | |
| $4.78 | +0.10 | +2.1% | $4.80 | $4.915 | $4.562 | 10,800 | |
| $4.68 | +0.21 | +4.7% | $4.48 | $4.795 | $4.48 | 17,400 | |
| $4.47 | -0.28 | -5.9% | $4.61 | $4.995 | $4.26 | 20,300 | |
| $4.75 | +0.01 | +0.2% | $4.83 | $4.99 | $4.66 | 9,500 | |
| $4.74 | -0.36 | -7.1% | $4.81 | $5.00 | $4.74 | 14,300 | |
| $5.10 | +0.325 | +6.8% | $4.95 | $5.14 | $4.90 | 11,000 | |
| $4.775 | -0.265 | -5.3% | $5.00 | $5.099 | $4.73 | 15,000 | |
| $5.04 | -0.095 | -1.9% | $5.07 | $5.10 | $5.03 | 2,900 | |
| $5.135 | -0.325 | -6.0% | $5.65 | $5.65 | $5.05 | 15,800 | |
| $5.46 | -0.47 | -7.9% | $5.81 | $6.015 | $5.32 | 23,100 | |
| $5.93 | -0.13 | -2.1% | $6.00 | $6.48 | $5.81 | 12,900 | |
| $6.06 | +0.02 | +0.3% | $5.99 | $6.17 | $5.91 | 7,500 | |
| $6.04 | -0.27 | -4.3% | $6.40 | $6.40 | $6.02 | 14,800 | |
| $6.31 | +0.25 | +4.1% | $6.09 | $6.31 | $6.01 | 29,500 | |
| $6.06 | +0.18 | +3.1% | $5.96 | $6.11 | $5.915 | 39,700 | |
| $5.88 | -0.08 | -1.3% | $6.112 | $6.112 | $5.77 | 23,400 | |
| $5.96 | +0.08 | +1.4% | $6.05 | $6.06 | $5.79 | 27,700 | |
| $5.88 | +0.08 | +1.4% | $5.76 | $6.17 | $5.68 | 22,100 | |
| $5.80 | -0.24 | -4.0% | $5.94 | $6.39 | $5.70 | 25,800 | |
| $6.04 | +0.11 | +1.9% | $5.97 | $6.315 | $5.841 | 37,400 | |
| $5.93 | -0.57 | -8.8% | $6.63 | $6.63 | $5.90 | 32,400 | |
| $6.50 | +0.27 | +4.3% | $6.29 | $6.67 | $6.17 | 56,800 | |
| $6.23 | -0.08 | -1.3% | $6.37 | $6.37 | $5.915 | 40,700 | |
| $6.31 | +0.81 | +14.7% | $5.60 | $6.44 | $5.41 | 36,500 | |
| $5.50 | +0.081 | +1.5% | $5.37 | $5.50 | $5.10 | 17,800 | |
| $5.419 | +0.119 | +2.2% | $5.31 | $5.55 | $5.04 | 77,600 | |
| $5.30 | -0.30 | -5.4% | $5.32 | $5.671 | $4.90 | 170,800 | |
| $5.60 | -0.27 | -4.6% | $6.02 | $6.15 | $5.56 | 33,900 | |
| $5.87 | +0.25 | +4.4% | $5.82 | $5.90 | $5.50 | 25,500 | |
| $5.62 | -0.165 | -2.9% | $5.84 | $5.84 | $5.55 | 5,800 | |
| $5.785 | -0.045 | -0.8% | $5.74 | $6.32 | $5.56 | 77,500 | |
| $5.83 | -0.075 | -1.3% | $5.77 | $6.552 | $5.75 | 72,100 | |
| $5.905 | -0.145 | -2.4% | $6.094 | $6.10 | $5.905 | 2,900 | |
| $6.05 | +0.37 | +6.5% | $5.70 | $6.365 | $5.70 | 20,600 | |
| $5.68 | -0.78 | -12.1% | $6.45 | $6.45 | $5.666 | 24,500 | |
| $6.46 | +1.19 | +22.6% | $5.05 | $6.75 | $5.05 | 135,900 | |
| $5.27 | +0.265 | +5.3% | $5.07 | $5.65 | $4.88 | 395,800 | |
| $5.005 | 0.00 | 0.0% | $5.005 | $5.005 | $4.81 | 1,200 | |
| $5.005 | -0.40 | -7.4% | $5.59 | $5.77 | $5.005 | 24,500 | |
| $5.405 | -0.035 | -0.6% | $5.50 | $5.60 | $5.284 | 9,900 | |
| $5.44 | +0.69 | +14.5% | $4.46 | $5.44 | $4.172 | 11,400 | |
| $4.75 | +0.19 | +4.2% | $4.47 | $4.97 | $4.47 | 13,600 | |
| $4.56 | +0.07 | +1.6% | $4.57 | $4.90 | $4.465 | 7,300 | |
| $4.49 | -0.095 | -2.1% | $4.63 | $4.70 | $4.19 | 27,400 | |
| $4.585 | +0.065 | +1.4% | $4.445 | $4.82 | $4.445 | 7,600 |
Splits
3 splits since 2022 · NASDAQ:NDRA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-35 | Consolidation | |
| 1-for-50 | Consolidation | |
| 1-for-20 | Consolidation |
- Ticker
- NASDAQ:NDRA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
ENDRA Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Latest deck · Sep 9, 2026
Investor Day (September 2026)
Investor day · 29 slides
Latest news
ENDRA Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 16, 2026
Closed $3.92 (-11.3%) on Nov 17, 2026
ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 17, 2026
Closed $4.49 (+0.4%) on Aug 17, 2026
ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing
Jun 25, 2026
Closed $4.30 (-31.4%) on Jun 25, 2026
ENDRA Life Sciences (NASDAQ: NDRA) Beats Q1 Expectations, TAEUS® Liver Imaging Advances and Strategic Review Acceleration Fuels Investor Awareness
May 27, 2026
Closed $5.36 (+3.1%) on May 27, 2026
ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
May 18, 2026
Closed $5.41 (+7.1%) on May 18, 2026
ENDRA Life Sciences Reports Multi-Site Validation of TAEUS(R) Liver Device Demonstrating MRI-like Accuracy and Reproducibility
May 15, 2026
Closed $5.05 (-12.0%) on May 15, 2026
ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility
May 14, 2026
Closed $5.74 (+1.4%) on May 14, 2026
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Mar 31, 2026
Closed $4.65 (-0.6%) on Mar 31, 2026
ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value
Mar 25, 2026
Closed $3.75 (+8.4%) on Mar 25, 2026
ENDRA Life Sciences Inc. on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 14 in the last 12 months · 141 in all · newest Nov 16, 2026 · oldest 2019
- Calls
- 18 calls with a replay · 18 with a transcript · latest Aug 22, 2024
- Decks
- 12 decks · latest Sep 9, 2026
Where ENDRA Life Sciences Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:NDRA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:NDRA | BOATS | United States | USD |
Valuation
Price/book 1.0× against a median of 0.7×: 6th lowest of 10 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $3.85M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.0×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.07
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ENDRA Life Sciences Inc. · NASDAQ:NDRA | US$5.36M | US$3.85M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 1.07 |
| Izotropic Corp. · CSE:IZO | US$6.30M | US$6.26M | n/a | n/a | n/a | n/a | n/a | n/a | 0.21 |
| Accuray Incorporated · NASDAQ:ARAY | US$6.20M | US$65.61M | n/a | 0.2× | n/a | 0.1× | −4.4% | 1.9× | 2.46 |
| NeuroOne Medical Technologies Corporation · NASDAQ:NMTC | US$5.94M | US$3.89M | n/a | 0.4× | n/a | 1.6× | −78.6% | 0.0× | 1.07 |
| Neola Medical AB · OMXSTO:NEOLA | US$5.46M | US$5.07M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | n/a |
| MEKICS Co., Ltd. · KRX:058110 | US$5.23M | US$2.04M | 6.6× | 0.2× | 1.3× | 0.2× | 7.7% | 0.1× | n/a |
| PT Hetzer Medical Indonesia Tbk · IDX:MEDS | US$5.16M | US$5.45M | n/a | n/a | n/a | 1.8× | n/a | 0.1× | n/a |
| Regentis Biomaterials Ltd. · AMEX:RGNT | US$5.05M | −US$3.90M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 2.00 |
| SeaStar Medical Holding Corporation · NASDAQ:ICU | US$4.97M | US$981,429 | n/a | 0.5× | n/a | 10.6× | −678.2% | 0.0× | 1.44 |
| WORK Medical Technology Group LTD · NASDAQ:WOK | US$4.84M | US$8.21M | n/a | 0.8× | n/a | 0.2× | −10.9% | 0.2× | 2.76 |
| Kelyniam Global, Inc. · OTC:KLYG | US$4.56M | US$4.84M | n/a | 1.4× | 31.9× | 6.6× | −6.0% | 0.6× | 1.15 |
| Median of the others | US$5.19M | US$4.96M | 6.6× | 0.4× | 16.6× | 0.7× | −8.4% | 0.1× | 1.44 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 25.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.54 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Alexander Tokman | CEO & Director |
| Richard Jacroux | Chief Financial Officer |
| Scott Sober | Head of Operations |
| Ziad Rouag | Head of Clinical and Regulatory |
Board
| Director | Role |
|---|---|
| Alexander Tokman | CEO & Director |
| Anthony DiGiandomenico | Director |
| Lou Basenese | Director |
| Michael Harsh | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| ENDRA Life Sciences (NASDAQ:NDRA) Q2 2024 Earnings Call | Thu, Aug 22, 2024 · 4:30 PM ET | Replay |
| ENDRA Life Sciences (NASDAQ:NDRA) Q1 2024 Earnings Call | Tue, May 14, 2024 · 4:30 PM ET | Replay |
| ENDRA Life Sciences (NASDAQ:NDRA) Q4 2023 Earnings Call | Thu, Mar 28, 2024 · 4:30 PM ET | Replay |
| ENDRA Life Sciences (NASDAQ:NDRA) Q3 2023 Earnings Call | Tue, Nov 14, 2023 · 4:30 PM ET | Replay |
| ENDRA Life Sciences (NASDAQ:NDRA) Q2 2023 Earnings Call | Mon, Aug 14, 2023 · 4:30 PM ET | Replay |
| ENDRA Life Sciences (NASDAQ:NDRA) Q1 2023 Earnings Call | Mon, May 15, 2023 · 4:30 PM ET | Replay |
| ENDRA Life Sciences (NASDAQ:NDRA) Q4 2022 Earnings Call | Tue, Mar 14, 2023 · 4:30 PM ET | Replay |
| ENDRA Life Sciences (NASDAQ:NDRA) Q3 2022 Earnings Call | Mon, Nov 14, 2022 · 4:30 PM ET | Replay |
| ENDRA Life Sciences (NASDAQ:NDRA) Q2 2022 Earnings Call | Mon, Aug 15, 2022 · 4:30 PM ET | Replay |
| ENDRA Life Sciences (NASDAQ:NDRA) Q1 2022 Earnings Call | Thu, May 12, 2022 · 4:30 PM ET | Replay |
All 18 calls
| Call | When | Status |
|---|---|---|
| ENDRA Life Sciences (NASDAQ:NDRA) Q4 2021 Earnings Call | Wed, Mar 30, 2022 · 4:30 PM ET | Replay |
| ENDRA Life Sciences (NASDAQ:NDRA) Q3 2021 Earnings Call | Mon, Nov 15, 2021 · 4:30 PM ET | Replay |
| ENDRA Life Sciences (NASDAQ:NDRA) Q2 2021 Earnings Call | Thu, Aug 12, 2021 · 4:30 PM ET | Replay |
| ENDRA Life Sciences (NASDAQ:NDRA) Q1 2021 Earnings Call | Mon, May 17, 2021 · 4:30 PM ET | Replay |
| ENDRA Life Sciences (NASDAQ:NDRA) Q3 2020 Earnings Call | Mon, Nov 16, 2020 · 3:30 AM ET | Replay |
| ENDRA Life Sciences (NASDAQ:NDRA) Q2 2020 Earnings Call | Mon, Aug 17, 2020 · 4:30 AM ET | Replay |
| ENDRA Life Sciences (NASDAQ:NDRA) Q1 2020 Earnings Call | Thu, May 14, 2020 · 4:30 AM ET | Replay |
| ENDRA Life Sciences (NASDAQ:NDRA) Q4 2020 Earnings Call | Wed, Mar 25, 2020 · 4:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · After close | −11.3% |
| Q2 2026 | Aug 14, 2026 · After close | +0.5% |
| Q1 2026 | May 15, 2026 · After close | +7.1% |
| Q3 2025 | Nov 14, 2025 · After close | −7.5% |
| Q2 2025 | Aug 14, 2025 · After close | +9.5% |
| Q1 2025 | May 15, 2025 | +3.2% |
| Q4 2024 | Mar 31, 2025 · Before open | +1.2% |
| Q3 2024 | Nov 15, 2024 · Before open | −14.2% |
| Q2 2024 | Aug 14, 2024 · After close | −5.6% |
| Q1 2024 | May 14, 2024 · After close | +0.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 28, 2024 · After close | −30.5% |
| Q3 2023 | Nov 14, 2023 · After close | +3.2% |
| Q2 2023 | Aug 14, 2023 · After close | −8.4% |
| Q1 2023 | May 15, 2023 · After close | +1.6% |
| Q4 2022 | Mar 14, 2023 · After close | −3.2% |
| Q3 2022 | Nov 14, 2022 · After close | |
| Q2 2022 | Aug 15, 2022 · After close | |
| Q1 2022 | May 12, 2022 · After close | |
| Q4 2021 | Mar 30, 2022 · After close | |
| Q3 2021 | Nov 15, 2021 · After close |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Day (September 2026) | Investor day | 29 slides | Sep 9, 2026 |
| Merger or Acquisition (June 2026) | Merger or acquisition | 39 slides | Jun 26, 2026 |
| Investor Presentation (June 2025) | Investor deck | 19 slides | June 2025 |
| Investor Presentation (January 2022) | Investor deck | 19 slides | Jan 7, 2022 |
| Investor Presentation (March 2021) | Investor deck | 19 slides | Mar 5, 2021 |
| Investor Presentation (January 2021) | Investor deck | 18 slides | Jan 11, 2021 |
| Investor Presentation (December 2020) | Investor deck | 19 slides | Dec 14, 2020 |
| Investor Presentation (September 2020) | Investor deck | 16 slides | Sep 2, 2020 |
| Investor Presentation (June 2020) | Investor deck | 15 slides | Jun 1, 2020 |
| Investor Presentation (December 2019) | Investor deck | 14 slides | Dec 19, 2019 |
All 12 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2018) | Investor deck | 22 slides | Jul 18, 2018 |
| Investor Presentation (June 2017) | Investor deck | 19 slides | Jun 2, 2017 |
Financings
| Raise | Date |
|---|---|
| Private placement of private investment in public equity (PIPE) Closed: US$4.9M raised · US$6.57 a share · Warrants at US$6.32 for 60 months · Lucid Capital Markets Dealers: Lucid Capital Markets (lead) Use of proceeds: Mostly to launch a digital asset treasury and buy cryptocurrency; the rest to complete the TAEUS pilot validation imaging study on MASLD/MASH | Oct 23, 2025 |
| At-the-market programme of common stock Closed: US$800,000 raised | May 15, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Declared effective by the SEC on Feb 12, 2019. Filed with the SEC to go public on Nov 21, 2016.
- Price range
- US$5.00 to US$5.50 a unit
- Units offered
- 1,400,000 units
- Offering size
- US$7 million to US$7.7 million · Units offered times the price range, worked out by 6ix
- Underwriters' option
- Up to 210,000 more units
- Listing
- NDRAU on the Nasdaq Capital Market
- Underwriters
- National Securities Corporation, Dougherty & Company · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 9, 2016 |
| Filed publicly | Nov 21, 2016 |
| Amended 13 times | Newest Jan 24, 2019 |
| Shares registered with an exchange | Dec 16, 2016 |
| Declared effective by the SEC | Feb 12, 2019 |
| Final prospectus, with the price | Not yet |
Filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jun 3, 2024 |
| CORRESP · Letter to the SEC | Jun 3, 2024 |
| UPLOAD · Letter from the SEC | Apr 29, 2024 |
| CORRESP · Letter to the SEC | Apr 1, 2024 |
| UPLOAD · Letter from the SEC | Feb 23, 2024 |
| S-1MEF · Registration of more shares for the same offering | Apr 28, 2023 |
| CORRESP · Letter to the SEC | Apr 24, 2023 |
| CORRESP · Letter to the SEC | Apr 24, 2023 |
| UPLOAD · Letter from the SEC | Apr 7, 2023 |
| 8-A12G · Registration of a class of shares | Sep 27, 2022 |
All 68 filings
Open IPO · From the cover of the amended prospectus (S-1/A) filed May 1, 2017
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.17K | 351.6K | 515.6K |
| Cost of revenue | 206.2K | 275.5K | 234.3K | 224.4K | 0 | 0 | 0 | 172.8K | 235.9K | |
| Gross profit | -206.2K | -275.5K | -234.3K | -224.4K | 0 | 0 | 6.17K | 178.8K | 279.7K | |
| Research and development | 1.85M | 3.19M | 5.00M | 6.55M | 5.48M | 5.92M | 6.57M | 4.72M | 1.93M | 495.4K |
| Selling, general and administrative | 3.72M | 7.06M | 4.70M | 5.17M | 4.94M | 5.00M | 3.86M | 3.75M | 2.75M | 1.54M |
| Operating income | -5.76M | -10.8M | -10.5M | -13.2M | -11.5M | -11.5M | -10.8M | -9.02M | -4.63M | -1.79M |
| Depreciation and amortization | 44.0K | 46.5K | 123.7K | 96.7K | 116.2K | 99.3K | 80.6K | 68.3K | 61.5K | 64.9K |
| EBITDA | -5.72M | -10.8M | -10.4M | -13.1M | -11.4M | -11.4M | -10.8M | -8.95M | -4.56M | -1.73M |
| Interest expense | 21.5K | 267.1K | 232.4K | 2.36M | 0 | 42.6K | 72.0K | |||
| Income before tax | -7.03M | -11.5M | -10.1M | -13.2M | -11.2M | -11.7M | -13.3M | -9.80M | -5.38M | -2.78M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net income | -7.03M | -11.5M | -10.1M | -13.2M | -11.2M | -11.7M | -13.3M | -9.80M | -5.38M | -2.78M |
| Earnings per share, basic | -8.93 | -56.94 | -1,694.50 | -4.56 | -5.55 | -0.63 | -2.34 | -2.17 | -1.95 | -3.84 |
| Earnings per share, diluted | -8.93 | -56.94 | -2,766.85 | -0.63 | -2.34 | -2.17 | -1.95 | -3.84 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 762.4K | 3.23M | 2.83M | 4.89M | 9.46M | 7.23M | 6.17M | 6.47M | 5.60M | 145.0K |
| Receivables | -2.62M | -1.35M | 390.8K | 116.7K | 0 | 6.85K | 0 | |||
| Inventory | 0 | 0 | 2.62M | 2.64M | 1.28M | 589.6K | 113.4K | 59.4K | 191.7K | 40.1K |
| Current assets | 968.0K | 3.43M | 3.03M | 5.38M | 12.1M | 8.21M | 6.54M | 6.95M | 5.88M | 195.6K |
| Property, plant and equipment | 42.5K | 69.3K | 111.8K | 235.7K | 131.1K | 212.2K | 236.3K | 273.2K | 241.5K | 295.2K |
| Total assets | 3.85M | 4.45M | 6.75M | 9.27M | 12.9M | 8.76M | 7.18M | 7.22M | 6.12M | 490.8K |
| Accounts payable | 383.0K | 269.7K | 360.4K | 614.0K | 791.1K | 402.9K | 1.28M | 631.5K | 780.3K | 227.7K |
| Current liabilities | 751.0K | 605.2K | 903.1K | 1.70M | 1.54M | 986.7K | 2.07M | 974.6K | 848.2K | 1.38M |
| Long-term debt | 28.5K | 337.1K | ||||||||
| Total debt | 492.4K | 0 | 28.5K | 28.5K | 546.6K | 769.3K | 773.3K | 23 | 950.0K | |
| Total liabilities | 1.59M | 1.89M | 1.10M | 2.07M | 2.09M | 1.60M | 2.42M | 974.6K | 848.2K | 1.38M |
| Shareholders' equity | 2.26M | 2.56M | 5.66M | 7.20M | 10.8M | 7.17M | 4.76M | 6.25M | 5.28M | -893.8K |
| Shares outstanding | 1.18M | 536.9K | 5.94K | 3.17M | 2.13M | 34.0M | 8.42M | 7.42M | 3.92M | 723.3K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -5.18M | -7.40M | -9.55M | -12.8M | -11.1M | -10.7M | -8.59M | -7.70M | -3.30M | -1.32M |
| Capital spending | -17.3K | -16.0K | -33.9K | -202.6K | -45.0K | -75.3K | -43.6K | -100.0K | -7.86K | -7.86K |
| Free cash flow | -5.20M | -7.42M | -9.58M | -13.0M | -11.2M | -10.8M | -8.63M | -7.80M | -3.31M | -1.32M |
| Cash from investing | -3.02M | -12.8K | -24.7K | -202.6K | -45.0K | -75.3K | -43.6K | -100.0K | -7.86K | 0 |
| Cash from financing | 5.73M | 7.81M | 7.52M | 8.40M | 13.4M | 11.9M | 8.34M | 8.67M | 8.77M | 1.44M |
| Dividends paid | -5.23K | -840 | -7.79K | -121.1K | -395.6K | -4.22M | ||||
| Share buybacks | 11.5M | 5.84M | 7.74M | 8.59M | 5.00K | |||||
| Change in cash | -2.47M | 395.6K | -2.06M | -4.57M | 2.23M | 1.05M | -297.2K | 869.5K | 5.46M | 125.8K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 425 | Nov 20, 2026 | Other filings | SEC |
| 425 | Nov 16, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 16, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 425 | Nov 6, 2026 | Other filings | SEC |
| 425 | Nov 5, 2026 | Other filings | SEC |
| 425 | Oct 26, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Oct 8, 2026 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Oct 8, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-4 · Registration statement | Oct 1, 2026 | Offer document | SEC |
| 425 | Oct 1, 2026 | Other filings | SEC |
| 8-K · Current report | Oct 1, 2026 | Material contract | SEC |
| 425 | Sep 25, 2026 | Other filings | SEC |
| 425 | Sep 14, 2026 | Other filings | SEC |
| 425 | Sep 9, 2026 | Other filings | SEC |
| 425 | Sep 9, 2026 | Other filings | SEC |
| 425 | Aug 20, 2026 | Other filings | SEC |
| 425 | Aug 20, 2026 | Other filings | SEC |
| 425 | Aug 17, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 17, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 425 | Aug 6, 2026 | Other filings | SEC |
| 425 | Aug 5, 2026 | Other filings | SEC |
| 425 | Aug 4, 2026 | Other filings | SEC |
| 425 | Jul 22, 2026 | Other filings | SEC |
| 425 | Jul 22, 2026 | Other filings | SEC |
| 425 | Jul 17, 2026 | Other filings | SEC |
| 425 | Jul 17, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 9, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 29, 2026 | Big-stake notice | SEC |
| 425 | Jun 26, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 26, 2026 | Material contract | SEC |
| 144 · Notice of proposed sale | Jun 25, 2026 | Other filings | SEC |
| 425 | Jun 25, 2026 | Other filings | SEC |
| 425 | Jun 25, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 25, 2026 | Current report | SEC |
| 8-K · Current report | May 28, 2026 | Material contract | SEC |
| RW · Request to withdraw a registration | May 26, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | May 15, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 21, 2026 | Current report | SEC |
| 10-K · Annual report | Mar 31, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2026 | Results | SEC |
| 8-K · Current report | Mar 25, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Dec 12, 2025 | Management or board change | SEC |
| 8-K · Current report | Nov 28, 2025 | Management or board change | SEC |
| SCHEDULE 13D · Big-stake notice | Nov 26, 2025 | Big-stake notice | SEC |
| 424B4 · Prospectus | Nov 26, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 14, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| S-3 · Registration statement | Nov 6, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 30, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 29, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 29, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 28, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Oct 28, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Oct 28, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 28, 2025 | Meeting notice | SEC |
| D | Oct 24, 2025 | Other filings | SEC |
| 8-K · Current report | Oct 23, 2025 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Oct 17, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 8-K/A · Current report, amended | Oct 15, 2025 | Material contract | SEC |
| 8-K · Current report | Oct 15, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| S-1/A · Registration statement, amended | Jul 25, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 23, 2025 | Current report | SEC |
| S-1/A · Registration statement, amended | Jul 16, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 9, 2025 | Results | SEC |
| S-1 · Registration statement | Jul 9, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2025 | Current report | SEC |
| 8-K · Current report | May 30, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| DRS · Draft registration statement | May 8, 2025 | Offer document | SEC |
| 10-K/A · Annual report, amended | Apr 4, 2025 | Annual report | SEC |
| S-8 · Registration statement for employee plans | Apr 2, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 22, 2024 | Current report | SEC |
| 10-Q/A · Quarterly report, amended | Nov 21, 2024 | Quarterly report | SEC |
| 10-Q · Quarterly report | Nov 19, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 15, 2024 | Results | SEC |
| NT 10-Q · Late filing notice | Nov 15, 2024 | Explanation request | SEC |
| 8-K · Current report | Nov 5, 2024 | Current report | SEC |
| 8-K · Current report | Oct 29, 2024 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Sep 16, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Sep 16, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Sep 6, 2024 | Meeting notice | SEC |
| 4/A · Change in ownership, amended | Sep 5, 2024 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 29, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 28, 2024 | Current report | SEC |
| 8-K · Current report | Aug 23, 2024 | Results | SEC |
| 8-K · Current report | Aug 16, 2024 | Current report | SEC |
| 3 · Initial statement of ownership | Aug 15, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2024 | Management or board change | SEC |
| 8-K · Current report | Aug 9, 2024 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Jul 17, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jul 17, 2024 | Current report | SEC |
| ARS · Annual report to shareholders | Jun 25, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jun 25, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jun 25, 2024 | Meeting notice | SEC |
| SC 13G · Big-stake notice | Jun 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jun 14, 2024 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Jun 12, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jun 6, 2024 | Material contract | SEC |
| 424B3 · Prospectus | Jun 5, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 5, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 3, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 3, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | May 31, 2024 | Offer document | SEC |
| 8-K · Current report | May 20, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| 8-K · Current report | May 10, 2024 | Results | SEC |
| S-1/A · Registration statement, amended | May 10, 2024 | Offer document | SEC |
| 8-K · Current report | May 3, 2024 | Current report | SEC |
| UPLOAD · Letter from the SEC | Apr 29, 2024 | Other filings | SEC |
| S-1 · Registration statement | Apr 19, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 4, 2024 | Other filings | SEC |
| 424B5 · Prospectus | Apr 3, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Apr 3, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 1, 2024 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 28, 2024 | Offer document | SEC |
| S-3/A · Registration statement, amended | Mar 28, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 28, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2024 | Results | SEC |
| UPLOAD · Letter from the SEC | Feb 23, 2024 | Other filings | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
| S-3 · Registration statement | Feb 14, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Dec 29, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 424B5 · Prospectus | Aug 14, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2023 | Results | SEC |
| 8-K · Current report | Aug 10, 2023 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Jul 25, 2023 | Meeting notice | SEC |
| 8-K · Current report | Jul 25, 2023 | Current report | SEC |
| 8-K · Current report | Jul 6, 2023 | Current report | SEC |
| DEFA14A · Additional proxy material | Jul 6, 2023 | Meeting notice | SEC |
| ARS · Annual report to shareholders | May 24, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 24, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 24, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | May 22, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | May 15, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2023 | Results | SEC |
| 4 · Change in ownership | May 3, 2023 | Insider trade | SEC |
| 8-K · Current report | May 2, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Apr 28, 2023 | Offer document | SEC |
| S-1MEF · Registration of more shares for the same offering | Apr 28, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 28, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 24, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 24, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Apr 18, 2023 | Offer document | SEC |
| 8-K · Current report | Apr 18, 2023 | Results | SEC |
| S-1/A · Registration statement, amended | Apr 18, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Apr 7, 2023 | Other filings | SEC |
| S-1 · Registration statement | Mar 30, 2023 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 16, 2023 | Offer document | SEC |
| 10-K · Annual report | Mar 16, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 14, 2023 | Results | SEC |
| SC 13G · Big-stake notice | Mar 10, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 1, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 23, 2022 | Management or board change | SEC |
| 8-K · Current report | Dec 19, 2022 | Material contract | SEC |
| 4 · Change in ownership | Dec 13, 2022 | Insider trade | SEC |
| 8-K · Current report | Dec 8, 2022 | Current report | SEC |
| 8-K · Current report | Dec 2, 2022 | Meeting outcome | SEC |
| 4 · Change in ownership | Nov 28, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 14, 2022 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2022 | Results | SEC |
| DEFA14A · Additional proxy material | Oct 17, 2022 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 17, 2022 | Meeting notice | SEC |
This page holds 200 of 551 filings. Open Filings
Cap table
Built by 6ix from ENDRA Life Sciences Inc.’s releases · as of Oct 23, 2025
- Common shares
- 1,499,912
- Fully diluted
- 1,499,912
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,499,912 |
Warrants and options
| Lot |
|---|
| Warrants · US$6.32 · expire about Oct 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,499,912 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Anthony DiGiandomenico Other companies: Illumination Acquisition Corp I (Director · Since at least Feb 26, 2026); ClearSign Technologies Corporation (Director · Since at least May 22, 2025); eXoZymes Inc. (Board Member · Since at least Nov 8, 2024); MDB Capital Holdings, LLC (Co-Founder, Head of New Venture Discovery · Since at least Jul 25, 2023); Provention Bio Inc (Director · Jul 3, 2018 – May 15, 2020 · Past); Cue Biopharma, Inc. (Director · Dec 18, 2017 – Jan 2, 2019 · Past); Charlie's Holdings, Inc. (Director · Aug 4, 2006 – Aug 27, 2012 · Past) | Director · Since at least May 8, 2017 |
| David R. Wells Other companies: Fusemachines Inc. (Chief Financial Officer · Since at least Sep 1, 2026); Functional Brands, Inc. (Chief Financial Officer, Director · Since at least May 18, 2026); HeartSciences Inc. (Board Member · Since at least Dec 28, 2022); Envoy Medical, Inc. (Chief Financial Officer · Sep 29, 2023 – Oct 15, 2023 · Past); Sionix Corporation (President, CFO, Director · Dec 16, 2009 – May 7, 2012 · Past) | Chief Financial Officer · May 8, 2017 – Apr 5, 2021 · Past |
| Alexander Tokman Other companies: MicroVision, Inc. (President and CEO, Director · Apr 13, 2006 – Feb 8, 2017 · Past) | CEO & Director · Since at least May 8, 2017 |
| Lou Basenese Other companies: ClearSign Technologies Corporation (Director · Since at least May 22, 2025) | Director · Since at least Apr 9, 2020 |
| Renaud Bertrand Maloberti Other companies: Bionik Laboratories Corp. (Chief Commercial Officer · Jun 11, 2018 – Jun 11, 2018 · Past) | Chief Commercial Officer · May 28, 2019 – Mar 28, 2022 · Past |
| Lou Basenese | Director · Since at least Nov 4, 2026 |
| Michael Harsh | Director · Since at least Jun 11, 2025 |
| Richard Jacroux | Chief Financial Officer · Since at least Nov 22, 2024 |
| Scott Sober | Head of Operations · Since at least Nov 4, 2026 |
| Ziad Rouag | Head of Clinical and Regulatory · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about ENDRA Life Sciences Inc.